Results 61 to 70 of about 23,280 (257)

Cyclosporine-induced kidney damage was halted by sitagliptin and hesperidin via increasing Nrf2 and suppressing TNF-α, NF-κB, and Bax

Scientific Reports
Cyclosporine A (CsA) is employed for organ transplantation and autoimmune disorders. Nephrotoxicity is a serious side effect that hampers the therapeutic use of CsA.
Ahmed M. Abd-Eldayem, Sohayla Mahmoud Makram, B. Messiha, H. H. Abd-Elhafeez, M. A. Abdel-Reheim   +4 more
semanticscholar   +1 more source

Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?

InflammoPharmacology, 2022
Coronavirus disease 2019 (Covid-19) is caused by severe acute respiratory syndrome type 2 (SARS-CoV-2). Covid-19 is characterized by hyperinflammation, oxidative stress, and multi-organ injury (MOI) such as acute lung injury (ALI) and acute respiratory ...
B. Alomair, H. Al-kuraishy, Ali K. Al-buhadily, A. Al-Gareeb, M. De Waard, E. Elekhnawy, G. Batiha   +6 more
semanticscholar   +1 more source

Sitagliptin Monoterapisi ile Kombinasyon Tedavilerinin Karşılaştırılması

Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2019
Çalışmamızda sitagliptinin monoterapide ve kombinasyon (metformin veya pioglitazon) tedavilerinde kullanımlarının glisemik kontrol, lipid profili ve insülin direnci üzerine etkilerinin karşılaştırılması amaçlanmıştır.
Özen Öz Gül, Pınar Şişman, Soner Cander, Canan Ersoy   +3 more
doaj   +1 more source

Solvation effects, structural, vibrational analysis, chemical reactivity, nanocages, ELF, LOL, Docking and MD simulation on Sitagliptin

Chemical Physics Impact
Sitagliptin is a medication used to manage type-2 diabetes. The present study investigates the experimental and theoretical results of Sitagliptin (SG). Density functional theory (DFT) calculations were used to determine optimized parameters at the B3LYP
G. Venkatesh, S. Haseena, P. Vennila, Y. Sixto-López, V. Siva, J. N. Cheerlin Mishma, S. Azad, Y. Mary   +7 more
semanticscholar   +1 more source

Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)

Cardiovascular Diabetology, 2020
BackgroundFew prospective studies have compared the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors.
A. Fuchigami, Fumika Shigiyama, Toru Kitazawa, Y. Okada, T. Ichijo, M. Higa, T. Hiyoshi, I. Inoue, Kaoru Iso, H. Yoshii, T. Hirose, Naoki Kumashiro   +11 more
semanticscholar   +1 more source

Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in Beta Cell Function in Patients with Type 2 Diabetes.

Diabetes, 2022
Dipeptidyl peptidase 4 (DPP-4) degrades the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). DPP-4 inhibitors improve glycemic control in type 2 diabetes, but the importance of protecting GIP from ...
Signe Stensen, L. Gasbjerg, M. Rosenkilde, T. Vilsbøll, J. Holst, B. Hartmann, M. Christensen, F. Knop   +7 more
semanticscholar   +1 more source

Sitagliptin and Fractures in Type 2 Diabetes: A Nationwide Population-Based Propensity-Matching Study

Frontiers in Pharmacology, 2018
Background: Sitagliptin, a dipeptidyl peptidase-4 inhibitor possibly affects bone turnover. We conducted this cohort study to determine whether sitagliptin is associated with an increased risk of fracture.Methods: The sitagliptin cohort included 1,578 ...
Shih-Yi Lin, Shih-Yi Lin, Wu-Huei Hsu, Wu-Huei Hsu, Cheng-Chieh Lin, Cheng-Chieh Lin, Cheng-Li Lin, Cheng-Li Lin, Chun-Hao Tsai, Chun-Hao Tsai, Hung-Chieh Yeh, Chung-Y. Hsu, Chia-Hung Kao, Chia-Hung Kao, Chia-Hung Kao   +14 more
doaj   +1 more source

Efficacy of Sitagliptin When Added to Ongoing Therapy in Korean Subjects with Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2011
BackgroundTo evaluate the clinical efficacy of sitagliptin for reducing plasma glucose levels in Korean subjects with type 2 diabetes mellitus during a 14-week treatment period.MethodsOur study design involved the addition of 100 mg sitagliptin once ...
Hye Soo Chung, Moon-Kyu Lee
doaj   +1 more source

Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial

Diabetologia
The aim of this study was to assess the efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes inadequately controlled with metformin treatment.
L. Ji, R. Agesen, S. Bain, Fang-Ming Fu, S. Gabery, Jianlin Geng, Yi-Ming Li, Yi-Bing Lu, Bifen Luo, Wuyan Pang, Y. Tao   +10 more
semanticscholar   +1 more source

The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial

Diabetologia
Dipeptidyl peptidase-4 (DPP-4) inhibition has beneficial effects on various metabolic indicators in diabetes. Stromal cell-derived factor-1 (SDF-1) is expressed in diverse organs including the kidneys and is cleaved and inactivated by DPP-4 enzyme.
N. Elbarbary, E. Ismail, M. El-Hamamsy, Marwa Z. Ibrahim, A. Elkholy   +4 more
semanticscholar   +1 more source